VNDA Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for VNDA from our risk checks.
Vanda Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.90 |
| 52 Week High | US$6.75 |
| 52 Week Low | US$3.44 |
| Beta | 0.77 |
| 11 Month Change | 3.59% |
| 3 Month Change | -7.55% |
| 1 Year Change | 39.60% |
| 33 Year Change | -71.73% |
| 5 Year Change | -70.76% |
| Change since IPO | -49.38% |
Recent News & Updates
Vanda's Struggles Persist Despite New Drug Launches And Takeover Bids
Sep 05Vanda Pharmaceuticals: I Believe That The Bidding War Is Not Over
Aug 08Recent updates
Vanda's Struggles Persist Despite New Drug Launches And Takeover Bids
Sep 05Vanda Pharmaceuticals: I Believe That The Bidding War Is Not Over
Aug 08Vanda Pharmaceuticals: Undervalued With Promising Pipeline And Acquisition Interest
Jun 18Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much
Apr 05Vanda Pharmaceuticals' (NASDAQ:VNDA) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Feb 15
Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash
Feb 13Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Low P/S No Reason For Excitement
Feb 10News Flash: One Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Analyst Has Been Trimming Their Revenue Forecasts
Nov 11One Forecaster Is Now More Bearish On Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Than They Used To Be
May 12Shareholder Returns
| VNDA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.3% | -6.5% | -1.0% |
| 1Y | 39.6% | 14.6% | 30.3% |
Return vs Industry: VNDA exceeded the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: VNDA exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| VNDA volatility | |
|---|---|
| VNDA Average Weekly Movement | 5.9% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VNDA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: VNDA's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 203 | Mihael Polymeropoulos | www.vandapharma.com |
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson’s disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia.
Vanda Pharmaceuticals Inc. Fundamentals Summary
| VNDA fundamental statistics | |
|---|---|
| Market cap | US$286.88m |
| Earnings (TTM) | -US$16.39m |
| Revenue (TTM) | US$190.86m |
1.5x
P/S Ratio-17.4x
P/E RatioIs VNDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VNDA income statement (TTM) | |
|---|---|
| Revenue | US$190.86m |
| Cost of Revenue | US$12.18m |
| Gross Profit | US$178.67m |
| Other Expenses | US$195.06m |
| Earnings | -US$16.39m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.28 |
| Gross Margin | 93.62% |
| Net Profit Margin | -8.59% |
| Debt/Equity Ratio | 0% |
How did VNDA perform over the long term?
See historical performance and comparison